

**Amendments to the Claims:**


This listing of claims will replace all prior versions, and listings of claims in the application.

**Listing of Claims:**

1. (Canceled).

2. – 5. (Canceled).

6. (Previously presented) The method of claim 43, wherein said substituted or unsubstituted 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA) has the formula:



wherein

R<sup>1a</sup> and R<sup>4a</sup> are members independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl and linker moieties;

X is a member selected from a lanthanide ion, an actinide ion, an alkaline earth metal ion, and a group IIIB transition metal ion;

Z<sup>1</sup>, Z<sup>2</sup>, Z<sup>3</sup> and Z<sup>4</sup> are members independently selected from OR<sup>1</sup> and NR<sup>1</sup>R<sup>2</sup>

in which

R<sup>1</sup> and R<sup>2</sup> are members independently selected from H, substituted or unsubstituted alkyl and substituted or unsubstituted heteroalkyl;

n is a member selected from 0 and 1.

7. (Cancelled).

8. (Previously presented) The method of claim 6, wherein the carbon atom marked \* is of S configuration.

1 9. (Cancelled)

1 10. (Previously presented) The method of claim 43, wherein said targeting moiety binds specifically  
2 to said cell surface antigen.

1 11. (Previously presented) The method of claim 43, wherein the targeting moiety is covalently  
2 attached to said antibody.

1 12. (Previously presented) The method of claim 10, wherein the targeting moiety is a second  
2 antibody.

1 13. (Original) The method of claim 11, wherein the targeting moiety specifically binds to a protein  
2 on a cancer cell.

1 14. (Previously presented) The method of claim 43, wherein the subject is a mammal.

1 15. (Previously presented) The method of claim 14, wherein the mammal is a human.

1 16-23. (Canceled)

1 24. (Previously presented) The method according to claim 43 wherein said antibody has the  
2 structure:



4 wherein,

5 n' is an integer selected from 1 to 10 ;

6 Ab represents said antibody;

7 L is a member selected from a chemical bond and a linking group that may contain one or  
8 more functional groups; and

9 T is said targeting moiety.

1 25. (Canceled).

1 26. (Previously presented) The method of claim 24, wherein said targeting moiety is a second  
2 antibody that binds specifically to a cell surface antigen.

1 27. (Previously presented) The method according to claim 24 wherein said antibody is administered  
2 to said subject as a pharmaceutical composition comprising said antibody and a pharmaceutically  
3 acceptable carrier.

1 28. (Canceled)

1 29. (Cancelled).

1 30. (Canceled)

1 31. (Canceled)

2 32. (Cancelled).

1 33. (Previously presented) The method according to claim 6, wherein

2  $R^{1a}$  and  $R^{4a}$  are H;

3  $Z^1$ ,  $Z^2$ ,  $Z^3$  and  $Z^4$  are OH;

4 and n is 1.

1 34. (Previously presented) The method according to claim 33, wherein said targeting moiety is a  
2 second antibody that binds specifically to a cell surface antigen.

1 35. (Previously presented) The method according to claim 34, wherein said targeting moiety is anti-  
2 CEA.

1 36. (Previously presented) The method according to claim 33, wherein said targeting moiety is anti-  
2 CEA.

1 37. (Canceled)


1 38. (Previously presented) The method according to claim 43, wherein said reactive site comprises  
2 sulfur.

1 39. (Cancelled)

1 40. (Previously presented) The method according to claim 6, wherein  $R^{1a}$  is a member independently  
2 selected from substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or  
3 unsubstituted aryl and linker moieties.

41. (Previously presented) The method according to claim 6, wherein  $R^{4a}$  is a member independently selected from substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl and linker moieties.

42. (Previously presented) The method according to claim 6, wherein said DOTA further comprises an arylalkyl moiety having a structure according to the formula:



wherein

$R^5$  is an unsubstituted unbranched alkyl linker;

$R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$  and  $R^7$  are members independently selected from H, halogen,  $NO_2$ , CN,  $X^1R^8$ ,  $NR^9R^{10}$ , and  $C(X^2)R^{11}$ ,

wherein

$X^1$  is a member selected from O, NH, and S;

$X^2$  is a member selected from O, S, and NH;

$R^8$  and  $R^9$  are members independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted heteroalkyl and  $C(Z^3)R^{12}$

wherein

$Z^3$  is a member selected from O, S and NH;

$R^{12}$  is a member selected from substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl and  $OR^{13}$

wherein

$R^{13}$  is a member selected from substituted or unsubstituted alkyl,

substituted or unsubstituted heteroalkyl, substituted or

unsubstituted aryl, and substituted or unsubstituted heteroaryl;

$R^{10}$  is a member selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, and OH, and

$R^9$  and  $R^{10}$  taken together are optionally ( $=C=S$ );

$R^{11}$  is a member selected from H, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl,  $OR^{14}$ , and  $NR^{15}R^{16}$ ,

27                    wherein  
28                    R<sup>14</sup> is a member selected from H, substituted or unsubstituted alkyl, substituted  
29                    or unsubstituted heteroalkyl, and C(O)R<sup>17</sup>,  
30                    wherein  
31                    R<sup>17</sup> is a member selected from substituted or unsubstituted alkyl, and  
32                    substituted or unsubstituted heteroalkyl; and  
33                    R<sup>15</sup> and R<sup>16</sup> are members independently selected from H, substituted or  
34                    unsubstituted alkyl, and substituted or unsubstituted heteroalkyl

43. (Previously presented) A method of treating a subject with cancer by administration of a macrocyclic metal chelate, said method comprising the steps of:

(a) administering to said subject an antibody comprising an antigen recognition domain that recognizes said macrocyclic metal chelate, wherein said antibody comprises:

i) a light chain comprising:

a) a first CDR having the sequence of SEQ ID NO:2;

b) a second CDR having a sequence selected from the group consisting of:

i) SEQ ID NO:3; and

ii) SEQ ID NO:3 containing a cysteine substitution wherein position 2 is substituted by a cysteine;

c) a third CDR having the sequence of SEQ ID NO:4;

ii) a heavy chain comprising:

a) a first CDR having the sequence of SEQ ID NO:6;

b) a second CDR having a sequence selected from the group consisting of:

i) SEQ ID NO:7;

ii) SEQ ID NO: 7 containing a cysteine substitution wherein position 5 has been substituted by a cysteine;

iii) SEQ ID NO:7 containing a cysteine substitution wherein position 6 has been substituted by a cysteine; and

iv) SEQ ID NO:7 containing a cysteine substitution wherein position 7 has been substituted by a cysteine;

c) a third CDR having the sequence of SEQ ID NO:8; wherein said antibody comprises at least one of said cysteine substitutions, and wherein said antibody binds substituted or unsubstituted 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA); and

a targeting moiety that binds specifically to a cancer cell by binding with a member selected from a cell surface receptor and cell surface antigen, thereby forming a cell-antibody complex; and

(b) administering to said subject said macrocyclic metal chelate, thereby forming a covalent bond between said reactive site and said reactive functional group.